The transplanted child: New immunosuppressive agents and the need for pharmacokinetic monitoring

Paediatrics and Child Health

Volumn 7, Issue 8, 2002, Pages 525-532

  Filler, Guido ^a   Feber, Janusz ^a  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

Area under the curve; Cyclosporine; Mycophenolate mofetil; Mycophenolic acid; Pharmacokinetics; Tacrolimus

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CANADA; CHILD; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; INFANT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MICROEMULSION; POSTOPERATIVE PERIOD;

EID: 0036814726     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/7.8.525     Document Type: Article

References (31)

1. Conley SB, Flechner SM, Rose G, Van Buren CT, Brewer E, Kahan BD. Use of cyclosporine in pediatric renal transplant recipients. J Pediatr 1985;106:45-9.
2. Jensen CW, Jordan ML, Schneck FX, et al. Pediatric renal transplantation under FK 506 immunosuppression. Transplant Proc 1991;23:3075-7.
3. van der Woude FJ. Mycophenolate mofetil (RS 61443): Nothing new under the sun or an important break-through in the field of transplantation? Nephrol Dial Transplant 1995;10:1112-5.
4. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993;136:5-28.
5. Virji M, Carter JE, Lirenman DS. Single-center experience with mycophenolate mofetil in pediatric renal transplant recipients. Pediatr Transplant 2001;5:293-6.
6. Clardy CW, Schroeder TJ, Myre SA, et al. Clinical variability of cyclosporine pharmacokinetics in adult and pediatric patients after renal, cardiac, hepatic, and bone-marrow transplants. Clin Chem 1988;34:2012-5.
7. Filler G, Ehrich J. Which cyclosporin formulation? Lancet. 1996;348:1176-7.
8. Filler G, Mai I, Filler S, Ehrich JH. Abbreviated cyclosporine AUCs on Neoral - The search continues! Pediatr Nephrol 1999;13:98-102.
9. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: Meta-analysis of randomised trials. BMJ 1999;318:1104-7.
10. Filler G, Grygas R, Mai I, et al. Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol Dial Transplant 1997;12:1668-71.
11. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995;345:1321-5.
12. Ettenger R, Menster B, Warshaw B, Potter D, Nichols A. Mycophenolate mofetil (MMF) in pediatric (ped) renal transplantation (TX): Final report of the pediatric MMF study group (PMMFSG). 16th Annual Meeting of the American Society of Transplant Physicians, 1997;Abstract 287.
13. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 1998;9:1511-20.
14. Jacqz-Agrain E, Khan Shaghaghi E, Baudouin V, et al. Pharmacokinetics and tolerance of mycophenoalte mofetil in pediatric renal transplant recipients. Pediatr Nephrol (In press).
15. Filler G, Lampe D, Mai I, Strehlau J, Ehrich JHH. Reduced dosing of MMF in combination with tacrolimus for steroid resistant, vascular rejection in renal allografts. Transpl Int 1998;11(Suppl 1):82-5.
16. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997;5:225-32.
17. Filler G, Ehrich JHH. Mycophenolic mofetil for rescue therapy in acute renal transplant rejection in children should always be monitored by measurement of trough concentration. Nephrol Dial Transplant 1997;12:374-5.
18. Shaw LM, Kaplan B, Kaufman D. Toxic effects of immunosuppressive drugs: Mechanisms and strategies for controlling them. Clin Chem 1996;42:1316-21.
19. Bauer S, Mai I, Roots I. Modification of the Abbott IMx Tacrolimus (FK-506) assay for estimation of low FK-506 blood levels. Naunyn-Schmiedeberg's Archives of Pharmacol 1996;353:R149.
20. Schütz E, Shipkova M, Armstrong VW, et al. Therapeutic drug monitoring of mycophenolic acid: Comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc 1998;30:1185-7.
21. Filler G, Lepage N, Delisle B, Mai I. Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. Ther Drug Monit 2001;23:514-9.
22. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Transplantation 2001;72:1024-32.
23. Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. BioDrugs 2001;15:279-90.
24. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000;14:100-4.
25. Kaplan B, Meier-Kriesche HU, Friedman G, et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol 1999;39:715-20.
26. Langman LJ, LeGatt DF, Halloran PF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation 1996;62:666-72.
27. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996;36:315-24.
28. Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit 2000;22:169-73.
29. Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, Miller J. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999;21:35-43.
30. Gregoor PJ, de Sevaux RG, Hene RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999;68:1603-6.
31. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001;23:119-28.